Brief: Celltrion Healthcare Announces Acceptance And Priority Review By Health Canada Of New Drug Submission For Its Monoclonal Antibody Treatment For Covid-19, Regdanvimab (Ct-P59)
Aug 2 (Reuters) - Celltrion HealthCare Co Ltd 091990.KQ :
* CELLTRION HEALTHCARE ANNOUNCES ACCEPTANCE AND PRIORITY
REVIEW BY
HEALTH CANADA OF NEW DRUG SUBMISSION FOR ITS MONOCLONAL ANTIBODY
TREATMENT FOR COVID-19, REGDANVIMAB (CT-P59)
Source text for Eikon: ID:nCNWr3V1Va
Further company coverage: 091990.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap